Innovation for the World, Exploring for the Future

SHENZHEN, China, July 1, 2024 /PRNewswire/ — Recently, the “Innovation for the World, Exploring for the Future” 2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm’s Series of Globalization Activities (China), organized by Kexing Biopharm, was successfully concluded in Shanghai. Numerous industry experts, senior figures from the domestic pharmaceutical and investment sectors, as well as senior executives of pharmaceutical companies from around 20 countries and regions, such as Brazil, Russia, Singapore, South Korea, Malaysia, Saudi Arabia, and Africa, who closely collaborated with Kexing Biopharm attended this forum on sharing and effective discussions on the current status and development trends in the global medical market.

During the forum, Kexing Biopharm warmly welcomed and sincerely thanked the attendees from various backgrounds who had traveled from afar. In addition, they provided a comprehensive introduction to the Company’s internationalization strategy and plans for the future. Kexing Biopharm emphasized its commitment to leveraging its overseas commercial platform to deliver high-quality products and comprehensive medication solutions for global patients. It specifically mentioned the successful acquisition of the EU GMP certificate for its first introduced product, albumin-bound paclitaxel, indicating a significant step forward in its global expansion. With a strong focus on international commercialization this year and leveraging years of international experience, the Company aims to become the best partner for high-quality Chinese pharmaceuticals worldwide.

Meanwhile, representatives from partner companies in Brazil, Malaysia, Saudi Arabia, and Africa, respectively shared insights into the local pharmaceutical development status, distribution channels, medication requirements, market access, and collaborative opportunities, providing clarification and showcasing the power of international win-win cooperation among the guests present at the event. Additionally, onsite strategic cooperation agreements were signed between Kexing Biopharm and various overseas partners, showcasing a reaffirmed commitment to continued collaboration and shared vision for the development of the pharmaceutical industry.

Simultaneously, during the CPHI exhibition from June 19th to 21, Kexing Biopharm presented a diverse portfolio of over twenty high-quality drugs covering the oncology pipeline, immunotherapy pipeline, metabolic disease pipeline, and nephropathy pipeline, including monoclonal antibodies, peptides, and small molecules.

Advertisement

News of victory keeps pouring in, on June 25, Kexing Biopharm (688136.SH) made it to the “2023 China Biopharmaceutical (Blood Product, Vaccine, and Insulin) Enterprise Top 20 List” in the “2023 China Pharmaceutical Industry Top 100 List Series,” which was the third time in a row.

View original content:https://www.prnewswire.co.uk/news-releases/2024-international-pharmaceutical-cooperation-high-end-forum-kexing-biopharms-series-of-globalization-activities-china-successfully-concluded-302186883.html

LONDON, July 1, 2024 /PRNewswire/ — Partners&, a leading independent insurance broker, is proud to announce the remarkable success of its partnership with YuLife, the tech-driven insurance company on a mission to inspire life. The collaboration, which began in 2021, has driven significant growth and unprecedented retention rates, transforming the insurance landscape for both companies and their customers.

YuLife’s innovative approach to insurance goes beyond traditional policies by offering group life, health, and income protection policies that actively enhance members’ physical, mental, financial, and social wellbeing. Through its unique model, YuLife incentivises people to build healthier habits, focusing on risk prevention rather than merely compensating claims.

Through the partnership, Partners& has achieved a 99% retention rate and has successfully won 39% of business from clients who previously had no insurance coverage. These impressive metrics highlight the true value of a win-win partnership – the transformative impact of YuLife’s innovative approach to insurance and Partners&’s commitment to delivering exceptional value.

“We are delighted with the outstanding results of our partnership with YuLife,” said Phil Barton, CEO of Partners&. “Our collaboration has not only fueled our business growth but has also brought transformative insurance solutions to our clients, promoting their holistic wellbeing. YuLife’s unique focus on inspiring healthier lifestyles aligns perfectly with our mission to provide comprehensive, client-centric insurance services.”

Key highlights of the partnership include:

Advertisement

Closing the protection gap: 39% of Partners& x YuLife customers are new to purchasing insurance.

Improving retention: Achieving over 99% retention rate, compared to an industry average of 80-85%.

Insurance that is loved: The Net Promoter Score (NPS) of  Partners& x YuLife is 96, over 3x the industry average.

High employee engagement: 73% of insured employees use the YuLife app regularly, over 10 times the average usage of standard consumer health apps.

“We are thrilled to see the tangible benefits of our partnership with Partners&,” said Sammy Rubin, CEO and Founder of YuLife. “Together, we are reshaping the insurance industry, providing clients with products that not only protect them but also enhance their overall wellbeing. Our shared commitment to innovation and employee engagement has been key to our success.”

Advertisement

About Partners&

Partners& is an award winning, Chartered insurance broker providing high quality, seamless insurance, employee benefits, risk management and claims advice to businesses and private clients. As a next generation insurance advisory business, Partners& combines the best traditions of broking, such as technical advice and client service, with modern thinking and intelligent use of technology, to enhance the client experience and create a dynamic workplace for its talented team. https://www.partnersand.com 

Media Contact

Malia Brown
Marketing and communications director
[email protected]
+44 7919 551962

About YuLife

Advertisement

YuLife is a tech-driven financial services brand on a mission to inspire life and turn financial products into a force for good. By harnessing the power of technology and the latest behavioural science, YuLife’s insurance model focuses on employee wellbeing and risk prevention, incentivising healthy daily behaviour to drive positive lifestyle outcomes. YuLife has quickly become a highly valued employee benefit, providing the safety net of insurance alongside a highly engaging wellbeing experience that fosters a healthier, happier and more motivated team. Founded in 2016, YuLife is headquartered in London and backed by global insurers and venture capital. https://www.YuLife.com/

Media Contact

Ben Crome
Headline Media
[email protected]
+44 7481 249328

View original content:https://www.prnewswire.co.uk/news-releases/partners-sees-99-retention-and-1-in-3-new-business-wins-in-game-changing-partnership-with-yulife-302186844.html

Advertisement

SAN FRANCISCO, July 1, 2024 /PRNewswire/ — sCrypt, a full-stack Web3/blockchain development platform, has announced the launch of its groundbreaking developer tool kit designed for the Unspent Transaction Output (UTXO) blockchains. The new tools will revolutionise how developers interact with UTXO blockchains, making them more accessible and fostering creativity in the Web3 space. 

UTXO is the method the Bitcoin protocol uses to track balances as they move between digital wallets. The UTXO model is essential for maintaining the security and integrity of blockchain networks and solves the double-spend problem. 

The sCrypt platform provides comprehensive toolkits such as Software Development Kits (SDK) and Application Programming Interfaces (APIs) that allow developers to seamlessly integrate UTXO blockchains into their applications. The platform will also integrate a vast ecosystem of JavaScript/TypeScript developers, estimated at 13 million globally. These developers can now leverage their existing skills to build and operate on UTXO blockchains. 

By doing so, sCrypt opens a world of opportunities, where developers are equipped with the best tools to drive innovation and success. 

The SDK provides libraries in various languages, detailed documentation, and tutorials and offer a flexible and robust framework for leveraging payments, tokens, and smart contracts. Whereas APIs allow developers to read from and write into blockchains, without setting up and maintaining their own nodes and indexers. As a tool kit, they allow developers to focus on the business logic of their dApp (decentralised applications), rather than worrying about the underlying blockchain infrastructure.

Advertisement

The platform is chain-agnostic, allowing developers to focus all their intellectual horsepower on application development rather than blockchain specifics. This industry-first platform is designed to power Web3 growth and empower developers to build and scale their dApp efficiently and effortlessly, by leveraging UTXO’s unparalleled scalability and programmability. 

Xiaohui Liu, Founder and CEO at sCrypt said, “Historically, Web3 applications have been largely built on account-based blockchains like Ethereum and Solana. Ordinals have brought renewed development interest back to Bitcoin and UTXO blockchains. With our extensive developer tooling and infrastructure, it is now easier than ever to build on UTXO blockchains, empowering builders to unleash UTXO’s superior scalability and programmability.”

Companies utilising the sCrypt platform include BTC platforms, such as Dotswap, the first BRC20 token swap platform on BTC, offer fast and seamless token exchanges, leveraging a fully functioning Automated Market Maker (AMM) and liquidity pools. It uses sCrypt’s APIs to query the status of tokens, including BRC20 and Runes. TierTopis another cutting-edge BTC trading platform that supports Ordinals NFTs, BRC-20 tokens, and bitmaps which rely on sCrypt’s token APIs.

Other businesses using sCrypt include Tokenovate, which leverages sCrypt’s smart contracts to manage trading lifecycle events of derivatives, such as interest-rate swaps and voluntary carbon credits. Additionally, various innovative applications benefiting from sCrypt’s toolkit are Hodlocker, Order Lock by RelayX, Tokenized, 1Sat Ordinals and Yours Wallet. 

The sCrypt platform is poised to be a game-changer for developers working within the UTXO framework, offering them resources to develop next-generation blockchain applications and aiming to become the de-facto development platform for UTXO blockchains. 

Advertisement

About sCrypt:
sCrypt is a UTXO-blockchain development platform that offers a suite of tools and infrastructure to enhance and accelerate the development process of decentralised applications (dApps). It provides a rich set of APIs and software development kits (SDKs) that simplify blockchain interactions, such as querying blockchain data, sending transactions, issuing tokens, and developing smart contracts. It specialises in UTXO blockchains and supports multiple of them, such as Bitcoin and Bitcoin SV.

View original content:https://www.prnewswire.co.uk/news-releases/scrypt-launches-chain-agnostic-developer-platform-for-utxo-blockchains-302186804.html